Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Learn more about Daniele’s recap of 2021 at GenomSys and his outlook for 2022 for himself and the company through the following quick questions:

Happy New Year Daniele and hello. What was your most outstanding achievement at GenomSys in 2021?

2021 was a challenging but very fruitful year. As a company, we grew significantly; we were able to launch our GenomSys Variant Analyzer for professionals and the GenomYou app for individuals; we improved and upgraded our MPEG-G Codec Suite, which is now the main engine for genomic data processing in all of our tools.

Personally, I have been involved in many interesting projects, first of all in the MPEG-G “nativization” of various tools used in the GenomSys Variant Analyzer and in the challenging task of porting complex algorithms, such as our codecs and the genomic analysis, to mobile platforms.

What was the most important thing you learned in 2021?

Along with the company growth, I learned more about cooperating with colleagues from different fields, which is now the case in GenomSys. From a technical point of view, I had the chance to learn a lot about genomic analysis algorithms and how genomic data are used and interpreted to produce solid clinical analysis results.

What are your expectations for you and/or GenomSys for 2022?

2021 has been the year when we laid the foundation for the next step to be achieved in 2022, which is bringing our products to the market and showing all the benefits that our vision and our approach can bring to the genomic market. It will be very exciting to finally take the MPEG-G standard and our codecs to the real world and show all the benefits it can provide in terms of compression efficiency, data privacy, faster access, and interoperability.

If you have any further questions for Daniele or about GenomSys, please feel free to contact us.

Picture: chrisreadingfoto / pixabay

Schedule a call

[contact-form-7 id="224" title="contact call"]